Otherside Farms
JANUARY 23, 2019
Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. abst – 2008). 2008] – PubMed result. A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. abst – 2008).
Greencamp
FEBRUARY 17, 2019
We produce endocannabinoids—internal cannabinoid-like compounds, that bind to these cellular endocannabinoid receptors. Cannabinoids: A Guide to 13 Bioactive Compounds from Weed. Cannabis research still has a long way to go regarding this topic, and it will take more clinical trials to fully understand how cannabis helps with IBS.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 6, 2021
“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”.
CannaMD
AUGUST 26, 2020
A new review published by scientific journal, Pharmacology Biochemistry and Behavior , has found that marijuana cannabinoid, CBD, is a “promising” therapy for treating cocaine dependence. Exploring alternative therapies, researchers turned their attention to marijuana cannabinoid, cannabidiol – more commonly referred to as CBD.
Project CBD
FEBRUARY 27, 2023
Researchers have been investigating the use of cannabis to treat fibromyalgia’s constellation of symptoms for decades, with early clinical trials in the 2000s 1-4 suggesting a possible benefit of both pure THC and flower in managing the disease. It’s not a new idea. That seemed to make all the difference.
The Cannigma
JANUARY 13, 2023
The authors noted that while “promising data are emerging on the possible role of ECS in migraine…proper placebo-controlled trials are needed to establish a therapeutic role for cannabinoids.” 1 A 2008 study found serotonin and endocannabinoid levels, including anandamide, were lower in people with chronic migraines.
CannaMD
NOVEMBER 15, 2020
research funders, the National Institute on Drug Abuse (NIDA) , spent over $1 billion between 2000 and 2008, with a heavily slanted focus on cannabis abuse and misuse, as well as the negative effects of cannabis. Non-profit organizations like the Canadian Consortium for Investigation of Cannabinoids (CCIC) were also formed to do research.
Expert insights. Personalized for you.
72 
Let's personalize your content